Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes
Diabetes Mellitus, Type 1, Blood Glucose
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Insulin-Dependent, Endocrine System Diseases, Blood glucose, Blood Glucose, Self-Monitoring
Eligibility Criteria
Inclusion Criteria:
- Type 1 diabetes
- Adult patients, age 18 or older and <75 years.
- Written Informed Consent
Exclusion Criteria:
- Pregnancy
- Patients with severe cognitive dysfunction or other disease which makes CGM use difficult.
Patients requiring continuous use of paracetamol. Paracetamol must not have been used
the week before the study and shall not be used during the duration because it disturbs the
interpretation of blood glucose levels estimated by the DexCom4G. However, other pain
killers can be used throughout the study period.
- Current CGM use
History of allergic reaction to any of the CGMS materials
or adhesives in contact with the skin.
History of allergic reaction to chlorhexidine or alcohol
anti-septic solution.
- Abnormal skin at the anticipated glucose sensor
attachment sites (excessive hair, burn, inflammation,
infection, rash, and/or tattoo).
Sites / Locations
- NU-hospital Organisation
- Uddevalla hospital
Arms of the Study
Arm 1
Other
comparisson CGM accuracy
Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose